Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same

Information

  • Patent Grant
  • 8945592
  • Patent Number
    8,945,592
  • Date Filed
    Friday, November 21, 2008
    15 years ago
  • Date Issued
    Tuesday, February 3, 2015
    9 years ago
Abstract
Compositions and methods effective to minimize or eliminate the presence of oxidative degradation products in solid dosage forms comprising sufentanil are provided.
Description
FIELD OF THE INVENTION

The present invention relates to compositions, methods and systems effective to minimize or eliminate the presence of oxidative degradation products in solid dosage forms comprising sufentanil. The solid dosage forms comprising sufentanil are packaged in a substantially oxygen impermeable container which includes at least one oxygen scavenging material.


BACKGROUND OF THE TECHNOLOGY

Many pharmaceutical formulations and reagents used in diagnostic evaluations are sensitive to oxygen and/or moisture. Exposure of such pharmaceutical formulations and reagents to oxygen may interfere with the stability and efficacy of the pharmaceutical agent or reagent.


The importance of providing pharmaceutical formulations in which an oxidation-susceptible active drug is protected against oxidative degradation, in particular, with prolonged storage or storage at elevated temperatures, is a concept well known to, and appreciated by, members of the pharmaceutical industry. Preservatives and antioxidants are often employed in the pharmaceutical formulation to address this problem.


Oxygen scavengers or displacement of oxygen with an inert gas in the headspace of a finished product has been used to reduce the generation of oxidative degradation products.


Degradation protectants for increasing the shelf-life of medical devices are described for example in U.S. Pat. No. 6,660,295 and United States Patent Publication Nos. 20010051180; 20040187438; and 20070084144. Oxygen scavenging packaging for pharmaceuticals and other oxygen sensitive products are described for example in United States Patent Publication Nos. 20020155233 and 20060076536.


Oxidative degradation of sufentanil has not been reported for liquid (Sufenta) or dry powder forms of sufentanil (Janssen Pharmaceuticals, and Johnson Matthey, Inc.). Surprisingly, oxidative degradation of sufentanil in low dose solid dosage forms prepared using aqueous and/or organic solvents has been observed.


There remains a need for development of specific pharmaceutical formulations and packaging systems to ensure that oxidation-susceptible drugs, such as sufentanil, can be formulated and stored in low dose solid dosage forms in a manner where oxidative degradation is minimized and the integrity of the active drug is maintained.


BRIEF SUMMARY OF THE INVENTION

Solid sufentanil drug dosage forms are provided in a primary package containing an oxygen scavenger, wherein the percentage of sufentanil oxidative degradation products is minimized or eliminated in solid sufentanil drug dosage forms packaged with an oxygen scavenger relative to solid sufentanil drug dosage forms packaged in the absence of an oxygen scavenger.


The packaged solid sufentanil drug dosage forms may be stored for at least 6 months under conditions selected from the group consisting of 5° C. and ambient humidity, 25° C. and 60% relative humidity and 40° C. and 75% relative humidity


The packaged solid sufentanil drug dosage forms may have a mass of less than 30 mg or a volume of less than 30 mcL or a mass of less than 10 mg or a volume of less than 10 mcL and may comprise 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, 40 mcg, 50 mcg, 60 mcg, 70 mcg, 80 mcg or 100 mcg of sufentanil.


The packaged solid sufentanil drug dosage forms may be housed in a drug delivery dispenser such as a cartridge or a single dose applicator and the primary package may be a foil pouch.


Methods for preventing oxidative degradation of solid sufentanil drug dosage forms are also provided.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 provides a graphic depiction of % Total RS versus time (0, 0.5, 1, 2, 3 and 6 months) for 5 mcg sufentanil dosage forms made using a standard formulation following storage at 5° C. and ambient humidity in HDPE bottles containing desiccant (5 ug—Desiccant in HDPE) or in HDPE bottles containing an oxygen scavenger (5 ug-R_Stabilox in HDPE).



FIG. 2 provides a graphic depiction of % Total RS versus time (0, 0.5, 1, 2, 3 and 6 months) for 5 mcg sufentanil dosage forms made using a standard formulation following storage at 25° C. and 60% relative humidity in HDPE bottles containing desiccant (5 ug—Desiccant in HDPE) or in HDPE bottles containing an oxygen scavenger (5 ug-R_Stabilox in HDPE).



FIG. 3 provides a graphic depiction of % Total RS versus time (0, 0.5, 1, 2, 3 and 6 months) for 5 mcg sufentanil dosage forms made using a standard formulation following storage at 40° C. and 75% relative humidity in HDPE bottles containing desiccant (5 ug—desiccant in HDPE) or in HDPE bottles containing an oxygen scavenger (5 ug-R_Stabilox in HDPE).





DETAILED DESCRIPTION OF THE INVENTION

I. Introduction


Provided herein are compositions, methods and systems effective to minimize or eliminate the presence of oxidative degradation products in solid dosage forms comprising sufentanil.


The following disclosure describes the compositions, methods and systems which constitute the invention. The invention is not limited to the specific dosage forms, devices, methodology, systems, kits or medical conditions described herein, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.


It must be noted that as used herein and in the appended claims, the singular forms “a”, “and”, and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, reference to “a drug formulation” includes a plurality of such formulations and reference to “a drug delivery device” includes systems comprising drug dosage forms and delivery devices for containment, storage and delivery of such dosage forms.


Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described.


The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such a disclosure by virtue of prior invention.


As used herein, the term “analgesic”, is used with reference to any of a number of drugs used to relieve pain (achieve analgesia).


The term “analgesic drug” is used herein with reference to a drug which results in analgesia following administration to a subject, for example, sufentanil, or a sufentanil congener, such as alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, or mirfentanil. The phrase “analgesic drug” is not limited to sufentanil, a sufentanil congener, or formulations comprising sufentanil or a sufentanil congener.


The term “antioxidant” as used herein refers to a molecule or combination of molecules capable of slowing or preventing the oxidation of other molecules. Oxidation is a chemical reaction that transfers electrons from a substance to an oxidizing agent. Oxidation reactions can produce free radicals. Antioxidants typically terminate these chain reactions by removing free radical intermediates, and inhibit other oxidation reactions by being oxidized themselves.


The term “cartridge” is used herein with reference to a replaceable, single use disposable cartridge configured to hold one or more drug dosage forms, typically 40 and in some cases up to 200 drug dosage forms. The cartridge may comprise a smart cartridge recognition system with a physical keyed feature on the cartridge, a bar code on the cartridge, a magnetic tag on the cartridge, an RFID tag on the cartridge, an electronic microchip on the cartridge, or a combination thereof. The cartridge may comprise one or more shipping tablets, wherein at least one shipping tablet is dispensed prior to dispensing of a drug dosage form.


The term “replaceable cartridge” or “disposable cartridge” is used with reference to a cartridge for housing drug dosage forms and is typically configured to hold 40 or more drug dosage forms, wherein the cartridge is designed to be used in a dispensing device and discarded after use.


As used herein, the term “degradation” refers to any change in a “drug”, “medication”, or “pharmacologically active agent” (such as the sufentanil in a sufentanil-containing solid dosage form) during storage, for example by hydrolysis and/or oxidation of the drug or other components/excipients contained in the formulation.


As used herein, the term “degradation agent” refers to an agent which is exposed to a “drug”, “medication”, or “pharmacologically active agent” (such as the sufentanil in a sufentanil-containing solid dosage form) and causes an undesirable by-product, such as oxidizing agents or moisture (water).


As used herein, the term “degradation protectant” refers to any material which protects against degradation of a “drug”, “medication”, or “pharmacologically active agent” (such as the sufentanil in a sufentanil-containing solid dosage form), e.g., an oxygen scavenger, a desiccant, an anti-oxidant or a combination thereof.


The term “desiccant” is used herein with reference to a sorbant, in the form of a solid, liquid, or gel which has an affinity for water, and absorbs or adsorbs moisture from it's surrounding, thus controlling the moisture in the immediate environment.


The term “drug”, “medication”, “pharmacologically active agent”, “therapeutic agent” and the like are used interchangeably herein and generally refer to any substance that alters the physiology of an animal and can be effectively administered by the oral transmucosal route.


The terms “formulation” and “drug formulation” as used herein refer to a physical composition containing at least one pharmaceutically active substance, which may be provided in any of a number of dosage forms for delivery to a subject. The dosage form may be provided to the patient as a lozenge, pill, capsule, membrane, strip, liquid, patch, film, gum, gel, spray or other form.


The term “hydrogel-forming preparation”, means a solid formulation largely devoid of water which upon contact with an aqueous solution, e.g., a bodily fluid, and in particular that of the oral mucosa, absorbs water in such a way that it forms a hydrated gel in situ. The formation of the gel follows unique disintegration (or erosion) kinetics while allowing for release of the therapeutic agent over time. Additionally, the term “hydrogel-forming preparation” describes a solid formulation largely devoid of water which upon contact with bodily fluids, and in particular those in the oral cavity, transforms into a film that releases the drug. Such films increase the surface area available for drug release and absorption thus enabling faster absorption of the drug.


As used herein, the term “oxygen scavenger” refers to chemical substance that is added to a drug formulation or reagent in order to reduce or eliminate the generation of unwanted oxidation products. In general, an “oxygen scavenger” is effective to absorb oxygen. The term “oxygen scavenger” may be used interchangeably with the terms “oxygen scavenging element” and “oxygen absorber”.


As used herein, the term “drug delivery dispenser” means the container which directly houses a drug, medication, or pharmacologically active agent. Examples include, a cartridge, a single dose applicator, a multiple dose applicator, a thermoplastic tray, a blister pack, a flexible container, and a rigid container.


As used herein, the term “drug dosage form” refers to a physical entity containing at least one drug, medication, or pharmacologically active agent for delivery to a subject. It may be in the form of a lozenge, pill, tablet, capsule, membrane, strip, powder, patch, film, gel, spray, gum or other form.


As used herein, the term “primary packaging” means the container which directly houses a drug, medication, or pharmacologically active agent. Examples include a foil pouch, a plastic container, a plastic film container, a blister pack, a glass container, and the like.


An exemplary foil pouch comprises one of more of aluminum, zinc, nickel, tin, iron, copper, chromium, cobalt, silver, gold, magnesium, manganese, lead, galvanized iron, and metal oxides.


The term “small volume sufentanil-containing drug dosage form” is used herein with reference to a small volume dosage form that contains an amount of sufentanil from about 2 micrograms (mcg) to about 200 mcg of sufentanil, e.g., 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, 40 mcg, 50 mcg, 60 mcg, 70 mcg, 80 mcg, 90 mcg, or 100 mcg or more of sufentanil.


The term “solid dosage form” or “solid drug dosage form” is used herein with reference to a dosage form that is a solid, e.g., a lozenge, a pill, a tablet, a membrane or a strip.


The term “subject” includes any subject, generally a mammal (e.g., human, canine, feline, equine, bovine, ungulate etc.), adult or child, in which treatment with a sufentanil-containing solid dosage form is desired. The terms “subject” and “patient” may be used interchangeably herein.


The term “substantially oxygen impermeable material” is used herein with reference to a material that allows the passage of little or no oxygen through the material.


Inhibition of Oxidative Degradation


Many drugs are susceptible to oxidative degradation. In particular, this is a problem when the drug is present as a low percentage of the overall drug formulation. In order to minimize or eliminate the presence of impurities in a drug formulation comprising an oxidation-susceptible active drug, and a dosage form made from such a formulation, e.g., a solid sufentanil dosage form, preservatives and antioxidants are often employed in the formulation to address this problem. In some cases, this is sufficient to minimize or eliminate the generation of oxidative degradation products. In other cases, additional measures may be required, such as use of a degradation protectant, e.g., an oxygen scavenger, when packaging the drug dosage form.


The oxygen-scavenger comprises a material suitable for effectively scavenging oxygen during drug storage, so that an oxidation-susceptible active drug, e.g., sufentanil, in a solid dosage form is not adversely affected by oxidation of the active drug.


Methods and compositions for protecting an oxidation-susceptible active drug, such as sufentanil, in a solid drug dosage form from oxidative degradation are disclosed. In some cases, the methods involve inclusion of an oxygen scavenger in the packaging for the drug dosage form. In this manner, drug dosage forms, e.g., sufentanil tablets, are produced and stored under conditions wherein the active drug is protected from oxidative degradation, thus facilitating storage of the drug dosage form over extended periods of time.


Additional protection against oxygen exposure may be afforded by employment of packaging techniques designed to minimize exposure of the active drug to oxygen and/or moisture. Exemplary packaging techniques include use of primary packaging wherein more than one oxygen scavenging material is employed alone or in combination with use of a desiccant.


In one exemplary approach, an anti-oxidant such as BHT is included in the drug formulation, a drug delivery dispenser (e.g., a cartridge) houses the drug dosage form(s), and an oxygen scavenger is included in the primary packaging for the drug delivery dispenser, wherein gas exchange is possible between the drug delivery dispenser and the oxygen scavenger in the primary package.


In another exemplary approach, an anti-oxidant such as BHT is included in the drug formulation, a desiccant is included in the drug delivery dispenser (e.g., a cartridge) which houses the drug dosage form(s), and an oxygen scavenger is included in the primary packaging wherein gas exchange is possible between the drug delivery dispenser and primary package.


In a related approach, the oxidative degradation of a drug such as sufentanil is reduced or eliminated by providing the drug in an oxygen impermeable primary package, such as a foil pouch, which comprises at least one oxygen scavenging material.


In yet another embodiment, the antioxidant and/or the desiccant material are incorporated into the material that is used to make the drug delivery dispenser or primary packaging. In another embodiment, drug delivery dispenser or primary packaging material is comprised of an antioxidant packaging material.


In a preferred embodiment, the drug delivery dispenser is comprised of a material that does not generate degradation products upon exposure to a solid dosage form containing a pharmaceutically active agent, such as sufentanil. Exemplary materials for use in packaging include, glass, polypropylene, polyethylene (e.g., high density polyethylene (HDPE) or low density polyethylene (LDPE), polyester, polystyrene, polyamide, fluoro polymers such as ACLAR®, ethylene covinyl alcohol (EVOH), polycarbonate, polyurethane, polyvinylidene chloride (PVDC), polyvinyl alcohol (PVA) copolymers thereof, or blends thereof.


Exemplary materials for use in manufacture of single dose applicators, include but are not limited to TecoFlex EG 80A, Polyisoprene, Zylar 220; NAS 30 (NEOS NOVA), Versaflex, CL2242 (GLS Corp), KR01 (Chevron Phillips), Housing Polymer, Delrin® acetal (DuPont), Polyester (Valox; Celanex), Polypropylene, Pro Fax PD702 (Basell) and the like.


Antioxidants


Antioxidants commonly employed in pharmaceutical formulations include, but are not limited to, vitamin E, ascorbic acid, BHT (butylated hydroxytoluene), BHA (butylated hydroxyanisole), propyl gallate, ascorbyl palmitate, biflavonoids and the like. An antioxidant may be included in the formulation of an oxidation-susceptible drug, such as sufentanil, in particular, when provided in low dose solid dosage forms.


Oxygen Scavengers


Suitable oxygen scavengers include any organic or inorganic material that can absorb oxygen, for example, iron oxide powders, ferrous salts such as ferrous sulfate or ferrous chloride, sulfites, bisulfites, reducing sulfur compounds such as dithionite, ascorbic acid and/or their salts, erythorbic acid and/or their salts, reducing organic compounds such as catechol and hydroquinone, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA). See, e.g. U.S. Patent Publication Nos. 20060076536, 20070084144, 20060260967.


A number of oxygen scavengers and moisture absorbents are commercially available and may be purchased alone or in packages, e.g., StabilOx® (Multisorb Technologies), cyclohexene methyl acrylated (EMCM) polymer (Chevron-Phillips Chemical Company) or Ciba's Specialty Chemical's SHELFPLUS™).


An oxygen scavenger may be included in the packaging in the form of pellets, canisters, packets, capsules, powders, solid materials, tablets, or as part of the packaging material itself.


Desiccants


Any commercial desiccant may be used, e.g., in the packaging of a solid sufentanil dosage form. Desiccants may be provided as pellets, canisters, packets, capsules, powders, solid materials, papers, boards, tablets, adhesive patches and films, and can be formed for specific applications, including injection moldable plastics. Exemplary solid desiccants include, silica gel (sodium silicate), alumino-silicate, activated alumina, zeolite, molecular sieves, montmorillonite clay, calcium oxide and calcium sulfate.


In some embodiments, one or more desiccants may be employed in a drug delivery dispenser, e.g., within a cartridge or single dose applicator containing drug dosage forms, or inside the primary packaging for the drug-containing drug delivery dispenser, as a means for protecting solid drug dosage forms from moisture. Exemplary locations include, in or adjacent the dosage form or delivery pathway, in or adjacent a tablet magazine or cartridge, in or adjacent other components of a dispensing device, formed as an injection molded component of a dispensing device, and any other location within or without the device wherein the desiccant is in sufficiently close proximity to the drug dosage form to pick up moisture.


Solid Dosage Forms


In general, small volume solid dosage forms containing from about 2 mcg to about 200 mcg of sufentanil are used for oral transmucosal drug delivery. The dosage forms contain sufentanil, alone or in combination with another drug, e.g., a benzodiazepine such as triazolam.


The process for manufacture of solid dosage forms, e.g., tablets, pills, capsules, strips, films, powders, lozenges, membranes, patches, film or other forms, comprising sufentanil, typically involves the use of an aqueous and/or organic solvent.


The sufentanil-containing solid dosage forms have a mass of less than 100 mg or a volume of less than 100 mcL. More specifically, the dosage forms have a mass of less than 100 mg, 90 mg, 80 mg, 70 mg, 60 mg, 50 mg, 40 mg, 30 mg, 29 mg, 28 mg, 27 mg, 26 mg, 25 mg, 24 mg, 23 mg, 22 mg, 21 mg, 20 mg, 19 mg, 18 mg, 17 mg, 16 mg, 15 mg, 14 mg, 13 mg, 12 mg, 11 mg, 10 mg, 9 mg, 8 mg, 7 mg, 6 mg or 5 mg or a volume of less than 100 mcL, 90 mcL, 80 mcL, 70 mcL, 60 mcL, 50 mcL, 40 mcL, 30 mcL, 29 mcL, 28 mcL, 27 mcL, 26 mcL, 25 mcL, 24 mcL, 23 mcL, 22 mcL, 21 mcL, 20 mcL, 19 mcL, 18 mcL, 17 mcL, 16 mcL, 15 mcL, 14 mcL, 13 mcL, 12 mcL, 11 mcL, 10 mcL, 9 mcL, 8 mcL, 7 mcL, 6 mcL or 5 mcL. In one exemplary embodiment, the tablets have a mass of 5.85 mg. The dosage forms may have bioadhesive characteristics and may form a hydrogel upon contact with an aqueous solution.


Typical formulations for preparation of sufentanil-containing solid dosage forms and methods of making them are described in U.S. application Ser. Nos. 11/825,251 and 11/650,227, expressly incorporated by reference herein. An exemplary formulation is bioadhesive and comprises from about 0.04% to about 4% sufentanil, from about 0.08% to about 1.7% sufentanil or from abut 0.1% to about 2.0% sufentanil, e.g., about 0.04%, 0.08%, 0.1%, 0.2%, 2.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.2%, 2.2%, 2.4%, 2.5%, 2.6%, 2.8%, 3.0%, 3.2%, 3.5% or 4% sufentanil. In general, the formulation comprises: a non-ordered mixture of a pharmaceutically active amount of a drug; and a bioadhesive material which provides for adherence to the oral mucosa of the subject. Dissolution of a dosage form comprising the formulation is generally independent of pH, e.g., over a pH range of about 4 to 8.


Numerous suitable nontoxic pharmaceutically acceptable carriers for use in sufentanil-containing solid dosage forms can be found in Remington's Pharmaceutical Sciences, 17th Edition, 1985.


It will be understood that a sufentanil-containing formulation is converted into sufentanil-containing solid dosage forms for delivery to a subject using procedures routinely employed by those of skill in the art, such as direct compression, wet granulation, etc. The process for preparation of sufentanil-containing solid dosage forms typically involves use of aqueous and/or organic solvents and is optimized for each formulation in order to achieve high dose content uniformity.


Cartridges and Single Dose Applicators


The cartridge for housing drug dosage forms may be cylindrical, disk-shaped, helical, rectilinear, non-ordered, or may take the form of any assemblage of drug dosage forms that allows a drug dispensing device to dispense them in a controlled manner.


In one embodiment of the invention, a cartridge may hold sufficient drug dosage forms for 1-5 days of treatment, e.g., 40 tablets useful for 48 to 72 hours of treatment.


To prevent unused drug dosage forms from absorbing moisture or otherwise becoming exposed to moisture prior to use, a cartridge or other drug dispensing device may provide a means of sealing the drug dosage forms from exposure to moisture. This may accomplished by use of a cartridge that contains a desiccant or other absorbent or adsorbent material to absorb or adsorb moisture that penetrates the cartridge either prior to use or during normal use.


The desiccant is a sorbant, in the form of a solid, liquid, or gel that has an affinity for water, and absorbs or adsorbs moisture from the surrounding, thus controlling the moisture in the immediate environment. Any commercial desiccant may be used. Such commercial desiccants typically take the form of pellets, canisters, packets, capsules, powders, solid materials, papers, boards, tablets, adhesive patches, and films, and can be formed for specific applications, including injection moldable plastics. There are many types of solid desiccants, including silica gel (sodium silicate, which is a solid, not a gel), alumino-silicate, activated alumina, zeolite, molecular sieves, montmorillonite clay, calcium oxide and calcium sulfate, or others, any of which may be used in practicing the present invention.


In one embodiment, a single dose applicator (SDA) is used as the drug delivery dispenser for a solid sufentanil drug dosage form. In this embodiment, the SDA is contained in a primary package which is not oxygen permeable. In another embodiment, the SDA is contained in a primary package which is oxygen permeable. In yet another embodiment, the primary package is contained in a secondary package which is not oxygen permeable.


The SDA may contain the dosage form within, may have the drug dosage form attached or affixed to it, and/or may afford a seal against moisture, humidity, and light. The single dose applicator may be manually manipulated by a patient, healthcare provider, or other user to place the dosage form in the proper location for drug delivery.


The SDA may be provided as a pair of forceps, a syringe, a stick or rod, a straw, a pad, a capsule, a cup, a spoon, a strip, a tube, an applicator, a dropper, a patch, an adhesive pad, an adhesive film, a sprayer, an atomizer, or any other form suitable for the application of a single drug dosage form to the oral mucosa of a subject, e.g., the oral mucosa in the sublingual space. As will be understood by those of skill in the art, the SDA design may vary, so long as it is effective to place a drug dosage form, such as a tablet, in the desired location, e.g., in the sublingual space, in a manner that preserves integrity of the drug dosage form in the dispensing process. After use, the SDA is disposed of.


The dosage form may be provided in a drug delivery dispenser that consists of molded plastic or laminate that has indentations (“blisters”) into which a dosage form is placed, referred to herein as a “blister pack”. A blister pack may or may not have pre-formed or molded parts and may be used to package an SDA of any type.


SDAs may be provided in a child resistant multiple drug dispenser (MDD), which may serve to dispense the dosage forms housed therein or may be used for storage of a plurality of SDAs.


In one embodiment, an SDA serves as the drug delivery dispenser and an MDD serves as the primary package.


The dosage forms inside the SDA and MDD remain dry prior to dispensing a drug dosage form.


A desiccant may or may not be included in the drug delivery dispenser and an oxygen scavenger is typically included in the primary package.


Utility.


The presence of impurities in a pharmaceutical formulation that remain with the active pharmaceutical ingredient (API), develop during formulation, or develop upon aging of either API or formulated drug dosage forms can be problematic. The presence of such impurities even in small amounts may influence the efficacy and safety of a pharmaceutical product. Impurities in pharmaceutical products must be analyzed and identified. It is preferable that the total amount of active drug (e.g., sufentanil) degradation products not exceed 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1% or less of the amount of the active drug substance in a given drug dosage form. The International Conference on Harmonization (ICH) provides guidelines regarding the control of impurities.


The reduction or elimination of oxidative degradation products in drug dosage forms, e.g., solid dosage forms comprising sufentanil, can be achieved by inclusion of oxygen scavengers in the packaging for the drug dosage forms.


The preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof, both currently known equivalents and equivalents developed in the future. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein.


EXAMPLES
Example 1
Stability Studies with Solid Sufentanil Dosage Forms in the Presence and Absence of Oxygen Scavengers

A study was carried out to evaluate the stability of tablets comprising 5 mcg of sufentanil, having a mass of 5.85 mg following storage in high density polyethylene (HDPE) bottles for 0.5 months, 1 month, 2 months and 3 months under different environmental conditions with or without oxygen scavengers.


The storage conditions were the following:


(1) 5° C. at ambient humidity


(2) 25° C. and 60% relative humidity (RH)


(3) 40° C. and 75% relative humidity (RH)


The 5 mcg sufentanil formulation included 0.128% sufentanil citrate in a matrix of mannitol, hydroxypropylmethyl cellulose, stearic acid, magnesium stearate, dicalcium phosphate and butylated hydroxyl toluene (BHT), as follows.















Amount
% in


Component
Per Tablet (mg)
the Formulation

















Sufentanil Citrate
0.0075
0.128


Mannitol SD100
4.131
70.62


Di-Calcium Phosphate di-hydrate
1.170
20.00


HPMC K4M Premium CR
0.176
3.00


Stearic Acid
0.293
5.00


Mg Stearate
0.059
1.00


BHT
0.015
0.25


Total
5.850
100.00









The HPLC profile of solid sufentanil dosage forms stored with or without oxygen scavengers (StabilOx®; Multisorb) was evaluated following storage in HDPE bottles at T=0 and at 2 weeks, 1 month, 2 months, 3 months and 6 months. The stability of sufentanil was evaluated by HPLC analysis under the conditions set forth below. As will be understood by those of skill in the art, the conditions set forth below are exemplary conditions for HPLC analysis and are not intended to be limiting as to other possible methods of analysis.












Chromatographic System and Conditions
















Column
Waters XTerra RP18, 5 μm, 250 mm × 4.6 mm


Detection
235 nm


Column
30° C.


Temperature


Injection Volume
100 μL


Flow Rate
1.0 mL/min


Mobile Phase
MP A: 20 mM Ammonium Phosphate Buffer (pH 7.2)



MP B: Acetonitrile


Run Time
55 min



















Gradient Conditions









Time (min)
Mobile Phase A
Mobile Phase B












0
75
25


5
75
25


35
30
70


49
30
70


50
75
25


55
75
25









Samples analyzed for sufentanil degradation products were a composite of NanoTabs™ that provided about 50 ug/mL (of sufentanil) in solution. In carrying out the method, the number of NanoTabs™ and the volume needed to achieve a nominal concentration of about 50 μg/mL was calculated, then an amount of extraction solution equivalent to approximately 30% of the sample volume was pipetted into the container, the mixture was sonicated for 15 minutes, followed by dilution to volume with 20 mM ammonium phosphate buffer and thorough mixing. A glass syringe was used to filter the supernatant solution through a 0.45 μm Millipore Millex Nylon syringe filter. The first mL of filtrate was discarded, then the remainder was used to fill HPLC 9 mm TFE/SIL/TFE blue cap containers, followed by HPLC analysis.


Table 1A shows the results of HPLC analysis of solid sufentanil dosage forms for the presence of degradation products following storage at 5° C. and ambient humidity, as evidenced by peaks at relative retention times (RRT) of 0.37, 0.50 and 0.56 following storage in HDPE bottles for 2 weeks, 1 month, 2 months, 3 months and 6 months.









TABLE 1A







Stability Evaluation of 5 mcg Sufentanil Tablets at 5° C. and ambient


humidity.















2 wks
1 mo
2 mo
3 mo
6 mo


~RRT
T = 0
5° C.
5° C.
5° C.
5° C.
5° C.





0.37








0.50
0.39%
0.53%
0.59%
0.68%
0.84%
1.10%


0.56
0.19%
0.24%
0.25%
0.32%
0.39%
0.50%


% Total Deg
0.58%
0.77%
0.84%
1.00%
1.23%
1.60%





Total Deg. = Total degradation is reported as a percentage (%) of total sufentanil peak area.






Table 1B shows the results of HPLC analysis of solid sufentanil dosage forms for the presence of degradation products following storage at 5° C. and ambient humidity, as evidenced by peaks at relative retention times (RRT) of 0.37, 0.50 and 0.56 following storage in HDPE bottles containing an oxygen scavenger (Stabilox®; Multisorb Technologies) at T=0, 2 weeks, 1 month, 2 months, 3 months and 6 months.









TABLE 1B







Stability Evaluation of 5 mcg Sufentanil Tablets Stored at 5° C./ambient


humidity in HDPE Bottles Containing Oxygen Scavengers.















2 wks
1 mo
2 mo
3 mo
6 mo


~RRT
T = 0
5° C.
5° C.
5° C.
5° C.
5° C.





0.37

<0.1
<0.1





0.50
0.16%
<0.1
0.22%
0.21%
0.18%
0.14%


0.56

<0.1
0.13%
0.11%
0.10%



% Total Deg
0.16%
0.00%
0.35%
0.32%
0.28%
0.14%










FIG. 1 shows the % Total RS versus time (0, 0.5, 1, 2 and 3 months), for 5 mcg sufentanil dosage forms made using a standard formulation following storage at 5° C. and ambient humidity in HDPE bottles alone (5 ug) or containing an oxygen scavenger (Stabilox®; Multisorb Technologies; 5 ug-R). The designation “% Total RS” (% total related substances) means the same thing and is used interchangeably herein with the term “% SDP (percent sufentanil degradation products) which is the percentage of the peak area for “related substances” (sufentanil degradation products) relative to the total peak area for sufentanil.


Table 2A shows the results of HPLC analysis of solid sufentanil dosage forms for the presence of degradation products following storage at 25° C. and 60% RH, as evidenced by peaks at relative retention times (RRT) of 0.37, 0.50, 0.54 and 0.56 following storage in HDPE bottles containing an oxygen scavenger (Stabilox®), at T=0, 2 weeks, 1 month, 2 months, 3 months and 6 months.









TABLE 2A







Stability Evaluation of 5 mcg Sufentanil Tablets at 25° C. and 60% RH in HDPE


Bottles Containing Stabilox ®.















2 wks
1 mo
2 mo
3 mo
6 mo




25° C./60%
25° C./60%
25° C./60%
25° C./60%
25° C./60%


~RRT
T = 0
RH
RH
RH
RH
RH





0.37



0.11%
0.11%
0.19%


0.50
0.39%
0.86%
0.95%
1.28%
1.46%
1.69%


0.54





<0.1%


0.56
0.19%
0.40%
0.44%
0.61%
0.68%
0.76%


% Total Deg
0.58%
1.26%
1.39%
2.00%
2.25%
2.64%









Table 2B shows the results of HPLC analysis of solid sufentanil dosage forms for the presence of degradation products following storage at 25° C. and 60% RH, as evidenced by peaks at relative retention times (RRT) of 0.37, 0.50 and 0.56 following storage in HDPE bottles containing an oxygen scavenger (Stabilox®), at T=0, 2 weeks, 1 month, 2 months, 3 months and 6 months.









TABLE 2B







Stability Evaluation of 5 mcg Sufentanil Tablets Stored at 25° C. and 60% RH


in HDPE Bottles Containing Oxygen Scavengers.















2 wks
1 mo
2 mo
3 mo
6 mo




25° C./60%
25° C./60%
25° C./60%
25° C./60%
25° C./60%


~RRT
T = 0
RH
RH
RH
RH
RH





0.37

<0.1
<0.1
<0.1




0.50
0.16%
<0.1
<0.1
<0.1
0.10%
0.13%


0.56

<0.1
<0.1
<0.1




% Total Deg
0.16%
0.00%
0.00%
0.00%
0.10%
0.13%










FIG. 2 shows the % Total RS versus time (0, 0.5, 1, 2 and 3 months) for 5 mcg sufentanil dosage forms made using a standard formulation following storage at 25° C. and 60% humidity in HDPE bottles alone (5 ug) or containing an oxygen scavenger (5 ug-R).


Table 3A shows the results of analysis of solid sufentanil dosage forms for the presence of degradation products following storage at 40° C. and 75% RH, as evidenced by peaks at relative retention times (RRT) of 0.37, 0.50, 0.54 and 0.56 following storage in HDPE bottles at T=0, 2 weeks, 1 month, 2 months, 3 months and 6 months.









TABLE 3A







Stability Evaluation of 5 mcg Sufentanil Tablets Stored at 40° C. and 75%


RH in HDPE Bottles.















2 wks
1 mo
2 mo
3 mo
6 mo




40° C./75%
40° C./75%
40° C./75%
40° C./75%
40° C./75%


~RRT
T = 0
RH
RH
RH
RH
RH





0.37

0.11%
0.22%
0.38%
0.43%
0.42%


0.50
0.39%
0.86%
0.92%
1.09%
1.12%
1.00%


0.54





0.29%


0.56
0.19%
0.46%
0.52%
0.67%
0.64%
0.46%


% Total Deg
0.58%
1.43%
1.66%
2.14%
2.19%
2.17%









Table 3B shows the results of HPLC analysis of solid sufentanil dosage forms for the presence of degradation products following storage at 40° C. and 75% RH, as evidenced by peaks at relative retention times (RRT) of 0.37, 0.50 and 0.56 following storage in HDPE bottles containing an oxygen scavenger (Stabilox®), at T=0, 2 weeks, 1 month, 2 months, 3 months and 6 months.









TABLE 3B







Stability Evaluation of 5 mcg Sufentanil Tablets Stored at 40° C. and


75% RH in HDPE Bottles Containing Oxygen Scavengers.















2 wks
1 mo
2 mo
3 mo
6 mo




40° C./75%
40° C./75%
40° C./75%
40° C./75%
40° C./75%


~RRT
T = 0
RH
RH
RH
RH
RH





0.37

<0.1
<0.1
<0.1




0.50
0.16%
<0.1
<0.1
<0.1

0.56%


0.56

0.14%
0.28%
0.39%
0.32%



% Total Deg
0.16%
0.14%
0.28%
0.39%
0.32%
0.56%










FIG. 3 shows the % Total RS versus time (0, 0.5, 1, 2 and 3 months) for 5 mcg sufentanil dosage forms made using a standard formulation following storage at 40° C. and 75% humidity in HDPE bottles alone (5 ug) or containing an oxygen scavenger (5 ug-R).


Table 4 shows the results of HPLC analysis of solid sufentanil dosage forms for the presence of degradation products, following storage at 5° C. and ambient humidity in HDPE bottles+Stabilox® or without Stabilox®, reported as % Total RS versus time.









TABLE 4







Stability Evaluation of 5 mcg Sufentanil Tablets Stored at 5° C. and


Ambient Humidity in HDPE Bottles With or Without Oxygen Scavengers.









Time
% Total RS
% Total RS


(months)
(+ Stabilox ®)
(without Stabilox ®)












0
0.16
0.58


0.5

0.77


1
0.35
0.84


2
0.32
1.00


3
0.28
1.23


6
0.14
1.6









Table 5 shows the results of HPLC analysis of solid sufentanil dosage forms for the presence of degradation products following storage at 25° C. and 60% RH in HDPE bottles for 0, 0.5, 1, 2, 3 and 6 months in HDPE bottles+Stabilox® or without Stabilox®, reported as % Total RS versus time.









TABLE 5







Stability Evaluation of 5 mcg Sufentanil Tablets Stored at 25° C. and


60% RH in HDPE Bottles with or without Oxygen Scavengers.










% Total RS
% Total RS


time (months)
(+ Stabilox ®)
(without Stabilox ®)












0
0.16
0.58


0.5
0
1.26


1
0
1.39


2
0
2.15


3
0.1
2.15


6
0.13
2.64









Table 6 shows the results of HPLC analysis of solid sufentanil dosage forms for the presence of degradation products following storage at 40° C. and 70% RH, in HDPE bottles+Stabilox® or without Stabilox®, reported as % Total RS versus time.









TABLE 6







Stability Evaluation of 5 mcg Sufentanil Tablets Stored at 40° C. and


75% RH in HDPE Bottles with or without Oxygen Scavengers.










% Total RS
% Total RS


time (months)
(+ Stabilox ®)
(without Stabilox ®)












0
0.16
0.58


0.5
0.14
1.43


1
0.28
1.66


2
0.39
2.14


3
0.51
2.19


6
0.77
2.17









The results presented in Example 1 show that the generation of sufentanil degradation products following storage of solid sufentanil dosage forms is reduced or eliminated by storing the solid sufentanil drug dosage forms (e.g., tablets) in the presence of an oxygen scavenger.


Example 2
Stability Studies with Solid Sufentanil Dosage Forms in the Presence of Desiccant or Oxygen Scavengers

A study was carried out to evaluate the stability of tablets comprising 5 mcg of sufentanil, having a mass of 5.85 mg following storage in high density polyethylene (HDPE) bottles for 0.5 months, 1 month, 2 months, 3 months and 6 months under different environmental conditions in the presence of oxygen scavengers or desiccant.


The desiccant used was 1 g silica gel Sachet®.


The storage conditions were the following:


5° C. at ambient humidity;


25° C. and 60% relative humidity (RH); and


40° C. and 75% relative humidity (RH).


The sufentanil formulation and details of the HPLC procedure are provided in Example 1, above.


The HPLC profile of solid sufentanil dosage forms stored with StabilOx® or desiccant was evaluated following storage in HDPE bottles for 0.5 months, 1 month, 2 months, 3 months and 6 months.


Table 7 shows the results of HPLC analysis of solid sufentanil dosage forms for the presence of degradation products following storage in HDPE bottles at 5° C. and ambient humidity, reported as % total SDP at T=0 and at 0.5 months, 1 month, 2 months, 3 months and 6 months in the presence of an oxygen scavenger (5 ug-R_Stabilox®), or desiccant (5 ug—Desiccant).









TABLE 7







Stability Evaluation of 5 mcg Sufentanil Tablets Stored at 5° C. in HDPE


Bottles With Oxygen Scavengers or Desiccant.









Time
5ug-R_Stabilox ®
5ug - Desiccant in


(months)
in HDPE
HDPE












0
0.16
0.58


0.5

0.77


1
0.35
0.84


2
0.32
1.00


3
0.28
1.23


6
0.14
1.6









Table 8 shows the results of HPLC analysis of solid sufentanil dosage forms for the presence of degradation products following storage in HDPE bottles at 25° C. and 60% RH, reported as % total SDP at T=0 and at 0.5 months, 1 month, 2 months, 3 months and 6 months in the presence of an oxygen scavenger (5 ug-R_Stabilox®), or desiccant (5 ug—Desiccant).









TABLE 8







Stability Evaluation of 5 mcg Sufentanil Tablets Stored at Stored at 25° C.


and 60% RH in HDPE Bottles With Oxygen Scavengers or Desiccant.









Time
5ug-R_Stabilox ®
5ug - Desiccant in


(months)
in HDPE
HDPE












0
0.16
0.58


0.5
0
1.26


1
0
1.39


2
0
2.15


3
0.1
2.15


6
0.13
2.64









Table 9 shows the results of HPLC analysis of solid sufentanil dosage forms for the presence of degradation products following storage in HDPE bottles at 40° C. and 75% RH, reported as % total SDP at T=0 and at 0.5 months, 1 month, 2 months, 3 months and 6 months in the presence of an oxygen scavenger (5 ug-R_Stabilox®), or desiccant (5 ug—Desiccant).









TABLE 9







Stability Evaluation of 5 mcg Sufentanil Tablets Stored at Stored at 40° C.


and 75% RH in HDPE Bottles With Oxygen Scavengers or Desiccant.









Time
5ug-R_Stabilox ®
5ug - Desiccant in


(months)
in HDPE
HDPE












0
0.16
0.58


0.5
0.14
1.43


1
0.28
1.66


2
0.39
2.14


3
0.51
2.19


6
0.77
2.17









Example 3
Stability Studies with Solid Sufentanil Dosage Forms in Cartridges in the Presence of Oxygen Scavengers

Further studies were carried out on stability of solid sufentanil dosage forms following storage in cartridges comprising 40 tablets and StabilOx®. A study was carried out to evaluate the stability of tablets comprising 10 mcg of sufentanil, having a mass of 5.85 mg, following storage in cartridges for 1 month, 2 months, and 3 months under different storage conditions in the presence of an oxygen scavenger (Stabilox®).


The storage conditions were the following:


25° C. and 60% relative humidity (RH); and


40° C. and 75% relative humidity (RH).


The sufentanil formulation was the following: 0.256% sufentanil citrate in matrix of mannitol, hydroxypropylmethyl cellulose, stearic acid, magnesium stearate, dicalcium phosphate and butylated hydroxyl toluene (BHT).


The HPLC profile of solid sufentanil dosage forms stored with oxygen scavengers (an (Stabilox®) was evaluated following storage in cartridges for T=0, 1 month, 2 months and 3 months, using the conditions provided in Example 1, above.


Tables 10A and B show the results of HPLC analysis of solid sufentanil dosage forms for the presence of degradation products following storage in HDPE bottles or cartridges made of various materials and containing an oxygen scavenger, at 25° C. and 60% RH, as evidenced by peaks at relative retention times (RRT) of 0.36, 0.49/0.50 and 0.54/0.55 at T=0, 1 month, 2 months and 3 months.









TABLE 10A







Stability Evaluation of 10 mcg Sufentanil Tablets Stored at 25° C. and 60%


RH in HDPE Bottles or Cartridges With Oxygen Scavengers.











Polycarbonate Lexan HP2 Resin



“Control” HDPE Bottle
PC-HP2NR-Cartridge














~RRT
T = 0
T = 1 mo
T = 2 mo
T = 3 mo
T = 1 mo
T = 2 mo
T = 3 mo





0.36

<QL*
<QL
<QL
<QL
<QL
<QL


0.49/0.5
0.28
<QL
<QL
<QL
0.25
0.15
0.12


0.54/0.55
0.11
<QL
<QL
<QL
0.11
<QL
<QL


TOTAL
0.39
<QL


0.36





<QL means less than quantitation limit.













TABLE 10B







Stability Evaluation of 10 mcg Sufentanil Tablets Stored at 25° C. and 60%


RH in Cartridges With Oxygen Scavengers.










K-Resin-Cartridge
PCHP2R-Cartridge














~RRT
T = 0
T = 1 mo
T = 2 mo
T = 3 mo
T = 1 mo
T = 2 mo
T = 3 mo





0.36

<QL
<QL
<QL
<QL
<QL



0.49/0.5
0.28
0.30
0.22
0.22
0.48
<QL
<QL


0.54/0.55
0.11
0.13
0.11
0.11
0.23
<QL
<QL


TOTALS
0.39
0.43
0.33
<QL
0.71
<QL
<QL









Tables 11A and B show the results of HPLC analysis of solid sufentanil dosage forms for the presence of degradation products following storage in HDPE bottles or cartridges made of various materials and containing Stabilox®, at 40° C. and 75% RH, as evidenced by peaks at relative retention times (RRT) of 0.36, 0.49/0.50 and 0.54/0.55 at T=0, 1 month, 2 months and 3 months.









TABLE 11A







Stability Evaluation of 10 mcg Sufentanil Tablets Stored at 40° C. and 75%


RH in Cartridges With Oxygen Scavengers.










“Control”-HDPE Bottle
PC-HP2NR-Cartridge















T = 0
T = 1 mo
T = 2 mo
T = 3 mo
T = 1 mo
T = 2 mo
T = 3 mo





0.36

<QL
<QL
<QL
0.1
<QL
0.11


0.49/0.5
0.28
<QL
<QL
<QL
<QL
<QL
<QL


0.54/0.55
0.11
0.13
0.2
0.15
<QL
<QL
<QL


TOTALS
0.39
0.13
0.2
0.15
0.1
<QL
0.11
















TABLE 11B







Stability Evaluation of 10 mcg Sufentanil Tablets Stored at 40° C. and 75%


RH in Cartridges With Oxygen Scavengers.










K-Resin-Cartridge
PCHP2R-Cartridge















T = 0
T = 1 mo
T = 2 mo
T = 3 mo
T = 1 mo
T = 2 mo
T = 3 mo





0.36

I < QL
<QL
<QL
<QL
<QL
0.11


0.49/0.5
0.28
<QL
<QL
<QL
<QL
<QL
<QL


0.54/0.55
0.11
<QL
<QL
<QL
<QL
<QL
<QL


TOTALS
0.39
<QL
<QL
<QL
<QL
<QL
<QL









Example 4
Stability Studies with Solid Sufentanil Dosage Forms in Single Dose Applicators (SDAs) in the Presence of Oxygen Scavengers

Further studies were carried out on the stability of sufentanil in solid sufentanil dosage forms following storage in SDAs. A study was carried out to evaluate the stability of tablets comprising 10 mcg of sufentanil, having a mass of 5.85 mg following storage in SDAs for 1 month, 2 months and 3 months under different storage conditions in the presence of an oxygen scavenger (Stabilox®).


The storage conditions were the following:

  • 5° C. at ambient humidity;
  • 25° C. and 60% relative humidity (RH); and
  • 40° C. and 75% relative humidity (RH).


The sufentanil formulation is provided in Example 3, above.


The HPLC profile of solid sufentanil dosage forms stored in the presence of oxygen scavengers was evaluated following storage in SDAs for 1 month 2 months, and 3 months, using the conditions provided in Example 1, above.


Tables 12A and B show the results of HPLC analysis of solid sufentanil dosage forms for the presence of degradation products following storage in SDAs and packaging containing oxygen scavengers, at 25° C. and 60% RH, as evidenced by peaks at relative retention times (RRT)









TABLE 12A







Stability Evaluation of 10 mcg Sufentanil Tablets Stored at 2-8° C. and


Ambient Humidity in SDAs Packaged With Oxygen Scavengers.










Individual Unspecified Sufentanil Related



Time
Impurities (RS %)
Total (%)





T = 0
No Impurity was detected
N/A


T = 1 mo
No Impurity was detected
N/A


T = 2 mo
No Impurity was detected
N/A


T = 3 mo
No Impurity was detected
N/A










of 0.36, 0.49/0.50 and 0.54/0.55 at T=0, 1 month, 2 months and 3 months.









TABLE 12B







Stability Evaluation of 10 mcg Sufentanil Tablets Stored at 25° C. and


60% RH in SDAs Packaged With Oxygen Scavengers.












Individual Unspecified Sufentanil




Time
Related Impurities (RS %)
Total (%)







T = 0
No Impurity was detected
N/A



T = 1 mo
No Impurity was detected
N/A



T = 2 mo
No Impurity was detected
N/A



T = 3 mo
No Impurity was detected
N/A

















TABLE 12C







Stability Evaluation of 10 mcg Sufentanil Tablets


Stored at 40° C. and 75% RH in SDAs Packaged With Oxygen


Scavengers.












Individual Unspecified Sufentanil




Time
Related Impurities (RS %)
Total (%)







T = 0
No Impurity was detected
N/A



T = 1 mo
No Impurity was detected
N/A



T = 2 mo
No Impurity was detected
N/A



T = 3 mo
No Impurity was detected
N/A









Claims
  • 1. A packaged solid sufentanil drug dosage form comprising: (a) a solid sufentanil drug dosage form;(b) a primary package containing said solid sufentanil drug dosage form and an oxygen scavenger, wherein the percentage of sufentanil oxidative degradation products is minimized or eliminated in a solid sufentanil drug dosage form packaged with said oxygen scavenger relative to a solid sufentanil drug dosage form packaged in the absence of an oxygen scavenger.
  • 2. The packaged solid sufentanil drug dosage form according to claim 1, wherein the drug dosage form has a mass of less than 30 mg or a volume of less than 30 mcL.
  • 3. The packaged solid sufentanil drug dosage form according to claim 1, wherein the drug dosage form has a mass of less than 10 mg or a volume of less than 10 mcL.
  • 4. The packaged solid sufentanil drug dosage form according to claim 1, wherein the amount of sufentanil in said solid sufentanil drug dosage form is selected from the group consisting of 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, 40 mcg, 50 mcg, 60 mcg, 70 mcg, 80 mcg and 100 mcg of sufentanil.
  • 5. The packaged solid sufentanil drug dosage form according to claim 2, wherein the amount of sufentanil in said solid sufentanil drug dosage form is selected from the group consisting of 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, 40 mcg, 50 mcg, 60 mcg, 70 mcg, 80 mcg and 100 mcg of sufentanil.
  • 6. The packaged solid sufentanil drug dosage form according to claim 3, wherein the amount of sufentanil in said solid sufentanil drug dosage form is selected from the group consisting of 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, 40 mcg, 50 mcg, 60 mcg, 70 mcg, 80 mcg and 100 mcg of sufentanil.
  • 7. The packaged solid sufentanil drug dosage form according to claim 1, wherein said solid sufentanil drug dosage form is stored for at least 6 months under conditions selected from the group consisting of 5° C. and ambient humidity, 25° C. and 60% relative humidity and 40° C. and 75% relative humidity.
  • 8. The packaged solid sufentanil drug dosage form according to claim 5, wherein said solid sufentanil drug dosage form is stored for at least 6 months under conditions selected from the group consisting of 5° C. and ambient humidity, 25° C. and 60% relative humidity and 40° C. and 75% relative humidity.
  • 9. The packaged solid sufentanil drug dosage form according to claim 6, wherein said solid sufentanil drug dosage form is stored for at least 6 months under conditions selected from the group consisting of 5° C. and ambient humidity, 25° C. and 60% relative humidity and 40° C. and 75% relative humidity.
  • 10. The packaged solid sufentanil drug dosage form according to claim 1, further comprising a drug delivery dispenser for housing said solid sufentanil drug dosage form.
  • 11. The packaged solid sufentanil drug dosage form according to claim 10, wherein the drug delivery dispenser is a cartridge.
  • 12. The packaged sufentanil solid sufentanil drug dosage form according to claim 11, wherein the cartridge comprises a desiccant.
  • 13. The packaged solid sufentanil drug dosage form according to claim 10, wherein the drug delivery dispenser is a single dose applicator.
  • 14. The packaged solid sufentanil drug dosage form according to claim 10, wherein the primary package is a foil pouch.
  • 15. The packaged solid sufentanil drug dosage form according to claim 11, wherein the primary package is a foil pouch.
  • 16. The packaged solid sufentanil drug dosage form according to claim 13, wherein the primary package is a foil pouch.
  • 17. The packaged solid sufentanil drug dosage form according to claim 14, wherein oxidative degradation of the sufentanil in said solid sufentanil drug dosage form is not detectable after 6 months of storage at 5° C. and ambient humidity, 25° C. and 60% relative humidity or 40° C. and 75% relative humidity.
  • 18. A method for minimizing or eliminating oxidative degradation of a solid sufentanil drug dosage form comprising: (a) providing a solid sufentanil drug dosage form in a drug delivery dispenser;(b) further providing an oxygen scavenger;(c) placing said drug delivery dispenser and said oxygen scavenger in a primary package made of a substantially oxygen impermeable material, wherein the percentage of sufentanil oxidative degradation products is minimized or eliminated in said solid sufentanil drug dosage form packaged with said oxygen scavenger relative to a solid sufentanil drug dosage form packaged in the absence of an oxygen scavenger.
  • 19. The method according to claim 18, wherein the drug dosage form has a mass of less than 30 mg or a volume of less than 30 mcL.
  • 20. The method according to claim 18, wherein the drug dosage form has a mass of less than 10 mg or a volume of less than 10 mcL.
  • 21. The method according to claim 18, wherein the amount of sufentanil in said solid sufentanil drug dosage form is selected from the group consisting of 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, 40 mcg, 50 mcg, 60 mcg, 70 mcg, 80 mcg and 100 mcg of sufentanil.
  • 22. The method according to claim 18, wherein the solid sufentanil drug dosage form is stored for at least 6 months under conditions selected from the group consisting of 5° C. and ambient humidity, 25° C. and 60% relative humidity and 40° C. and 75% relative humidity.
  • 23. The method according to claim 18, wherein said drug delivery dispenser is a cartridge.
  • 24. The method according to claim 23, wherein the cartridge comprises a desiccant.
  • 25. The method according to claim 18, wherein the drug delivery dispenser is a single dose applicator.
  • 26. The method according to claim 18, wherein the primary package is a foil pouch.
US Referenced Citations (260)
Number Name Date Kind
2621655 Olson et al. Dec 1952 A
3444858 Russell May 1969 A
4020558 Cournut et al. May 1977 A
4226848 Nagai et al. Oct 1980 A
4229447 Porter et al. Oct 1980 A
4237884 Erikson Dec 1980 A
4474308 Bergeron Oct 1984 A
4582835 Lewis et al. Apr 1986 A
4671953 Stanley et al. Jun 1987 A
4764378 Keith et al. Aug 1988 A
4785969 McLaughlin Nov 1988 A
4863737 Stanley et al. Sep 1989 A
4873076 Fishman et al. Oct 1989 A
4880634 Speiser et al. Nov 1989 A
4950234 Fujioka et al. Aug 1990 A
5080903 Ayache et al. Jan 1992 A
5112616 McCarty et al. May 1992 A
5122127 Stanley et al. Jun 1992 A
5132114 Stanley et al. Jul 1992 A
5178878 Wehling et al. Jan 1993 A
5223264 Wehling et al. Jun 1993 A
5236714 Lee et al. Aug 1993 A
5288497 Stanley et al. Feb 1994 A
5288498 Stanley et al. Feb 1994 A
5296234 Hadaway et al. Mar 1994 A
5348158 Honan et al. Sep 1994 A
5352680 Portoghese et al. Oct 1994 A
5482965 Rajadhyaksha et al. Jan 1996 A
5489025 Romick Feb 1996 A
5489689 Mathew Feb 1996 A
5507277 Rubsamen et al. Apr 1996 A
5507807 Shippert Apr 1996 A
5657748 Braithwaite et al. Aug 1997 A
5660273 Discko, Jr. Aug 1997 A
5694919 Rubsamen et al. Dec 1997 A
5710551 Ridgeway et al. Jan 1998 A
5724957 Rubsamen et al. Mar 1998 A
5735263 Rubsamen et al. Apr 1998 A
5752620 Pearson May 1998 A
5785989 Stanley et al. Jul 1998 A
5800832 Tapolsky et al. Sep 1998 A
5827525 Liao et al. Oct 1998 A
5850937 Rauche et al. Dec 1998 A
5855908 Stanley et al. Jan 1999 A
5945651 Chorosinski et al. Aug 1999 A
5950632 Reber et al. Sep 1999 A
5954641 Kehr et al. Sep 1999 A
5968547 Reder et al. Oct 1999 A
5981552 Alam et al. Nov 1999 A
5995938 Whaley et al. Nov 1999 A
5997518 Laibovitz et al. Dec 1999 A
6024981 Khankari et al. Feb 2000 A
6039251 Holowko et al. Mar 2000 A
6116414 Discko, Jr. Sep 2000 A
6171294 Southam et al. Jan 2001 B1
6190326 McKinnon et al. Feb 2001 B1
6200604 Pather et al. Mar 2001 B1
6210699 Acharya et al. Apr 2001 B1
6216033 Southam et al. Apr 2001 B1
6230927 Schoonen et al. May 2001 B1
6234343 Papp et al. May 2001 B1
6248789 Weg et al. Jun 2001 B1
6264981 Zhang et al. Jul 2001 B1
6284512 Jones et al. Sep 2001 B1
6294999 Yarin et al. Sep 2001 B1
6310072 Smith et al. Oct 2001 B1
6319510 Yates et al. Nov 2001 B1
6328159 Discko, Jr. Dec 2001 B1
6350470 Pather et al. Feb 2002 B1
6358944 Lederman et al. Mar 2002 B1
6391335 Pather et al. May 2002 B1
6417184 Ockert et al. Jul 2002 B1
6425892 Southam et al. Jul 2002 B2
6484718 Schaeffer et al. Nov 2002 B1
6488953 Halliday et al. Dec 2002 B2
6495120 McCoy et al. Dec 2002 B2
6500456 Capella et al. Dec 2002 B1
6509036 Pather et al. Jan 2003 B2
6541021 Johnson et al. Apr 2003 B1
6576250 Pather et al. Jun 2003 B1
6599529 Skinhøj et al. Jul 2003 B1
6605060 O'Neil et al. Aug 2003 B1
6607750 Upadhyay et al. Aug 2003 B2
6641838 Pather et al. Nov 2003 B2
6642258 Bourrie et al. Nov 2003 B1
6645528 Straub et al. Nov 2003 B1
6651651 Bonney et al. Nov 2003 B1
6660295 Watanabe et al. Dec 2003 B2
6680071 Johnson et al. Jan 2004 B1
6682716 Hodges et al. Jan 2004 B2
6685951 Cutler et al. Feb 2004 B2
6689373 Johnson et al. Feb 2004 B2
6726053 Harrold Apr 2004 B1
6752145 Bonney et al. Jun 2004 B1
6759059 Pettersson et al. Jul 2004 B1
6761910 Pettersson et al. Jul 2004 B1
6762684 Camhi et al. Jul 2004 B1
6764696 Pather et al. Jul 2004 B2
6776978 Rabinowitz et al. Aug 2004 B2
6793075 Jeter et al. Sep 2004 B1
6796429 Cameron et al. Sep 2004 B2
6824512 Warkentin et al. Nov 2004 B2
6835194 Johnson et al. Dec 2004 B2
6855310 Rabinowitz et al. Feb 2005 B2
6881208 Phipps et al. Apr 2005 B1
6914668 Brestel et al. Jul 2005 B2
6916485 Aiache et al. Jul 2005 B2
6932983 Straub et al. Aug 2005 B1
6959808 Discko et al. Nov 2005 B2
6961541 Overy et al. Nov 2005 B2
6963289 Aljadeff et al. Nov 2005 B2
6969508 Dugger et al. Nov 2005 B2
6974590 Pather et al. Dec 2005 B2
6999028 Egbert et al. Feb 2006 B2
7018370 Southam et al. Mar 2006 B2
7018619 Rabinowitz et al. Mar 2006 B2
7044125 Vedrine et al. May 2006 B2
7044302 Conley et al. May 2006 B2
7070762 Rabinowitz et al. Jul 2006 B2
7070764 Rabinowitz et al. Jul 2006 B2
7070765 Rabinowitz et al. Jul 2006 B2
7072738 Bonney et al. Jul 2006 B2
7074935 Mathew et al. Jul 2006 B2
7078018 Rabinowitz et al. Jul 2006 B2
7078019 Rabinowitz et al. Jul 2006 B2
7078218 Smith et al. Jul 2006 B2
7090830 Hale Aug 2006 B2
7090866 Johnson et al. Aug 2006 B2
7119690 Lerch et al. Oct 2006 B2
7168626 Lerch et al. Jan 2007 B2
7169378 Rabinowitz et al. Jan 2007 B2
7198172 Hale et al. Apr 2007 B2
7208604 Mathew et al. Apr 2007 B2
7215295 Egbert et al. May 2007 B2
7248165 Collins et al. Jul 2007 B2
7276246 Zhang et al. Oct 2007 B2
7295890 Jean-Pierre et al. Nov 2007 B2
7306812 Zhang et al. Dec 2007 B2
7458374 Hale et al. Dec 2008 B2
7468179 Rabinowitz et al. Dec 2008 B2
7484642 Bonney et al. Feb 2009 B2
7500444 Bonney et al. Mar 2009 B2
7552728 Bonney et al. Jun 2009 B2
8202535 Palmer et al. Jun 2012 B2
20010020147 Staniforth et al. Sep 2001 A1
20020026330 Klein et al. Feb 2002 A1
20020037491 Halliday et al. Mar 2002 A1
20020071857 Kararli et al. Jun 2002 A1
20020110578 Pather et al. Aug 2002 A1
20020142050 Straub et al. Oct 2002 A1
20020160043 Coleman et al. Oct 2002 A1
20030008005 Cutler et al. Jan 2003 A1
20030015196 Hodges et al. Jan 2003 A1
20030015197 Hale et al. Jan 2003 A1
20030017175 Cutler et al. Jan 2003 A1
20030017994 Cutler et al. Jan 2003 A1
20030022910 Cutler et al. Jan 2003 A1
20030035776 Hodges et al. Feb 2003 A1
20030052135 Conley et al. Mar 2003 A1
20030052787 Zerhusen et al. Mar 2003 A1
20030077300 Wermeling et al. Apr 2003 A1
20030088236 Johnson et al. May 2003 A1
20030091629 Pather et al. May 2003 A1
20030099158 De la Huerga May 2003 A1
20030124185 Oshlack et al. Jul 2003 A1
20030130314 Druzgala et al. Jul 2003 A1
20030132239 Konig et al. Jul 2003 A1
20030171401 Johnson et al. Sep 2003 A1
20030173408 Mosher et al. Sep 2003 A1
20030181501 Le et al. Sep 2003 A1
20030185872 Kochinke et al. Oct 2003 A1
20030190290 Ross et al. Oct 2003 A1
20030232080 Pather et al. Dec 2003 A1
20040017567 Loicht et al. Jan 2004 A1
20040025871 Davies Feb 2004 A1
20040034059 Grarup et al. Feb 2004 A1
20040037882 Johnson et al. Feb 2004 A1
20040080515 Hagiwara et al. Apr 2004 A1
20040092531 Chizh et al. May 2004 A1
20040094564 Papp et al. May 2004 A1
20040096402 Hodges et al. May 2004 A1
20040120896 Dugger et al. Jun 2004 A1
20040133305 Jean Pierre Jul 2004 A1
20040157884 Johnson et al. Aug 2004 A1
20040158349 Bonney et al. Aug 2004 A1
20040170567 Sackler et al. Sep 2004 A1
20040180080 Furusawa et al. Sep 2004 A1
20040185003 Rabinowitz et al. Sep 2004 A1
20040191178 Cutler et al. Sep 2004 A1
20040202617 Rabinowitz et al. Oct 2004 A1
20040213855 Pettersson et al. Oct 2004 A1
20040248964 Crooks et al. Dec 2004 A1
20040253307 Hague et al. Dec 2004 A1
20050038062 Burns et al. Feb 2005 A1
20050049464 Lassers et al. Mar 2005 A1
20050054942 Melker Mar 2005 A1
20050064030 Pather et al. Mar 2005 A1
20050065175 Gonzales et al. Mar 2005 A1
20050075273 Rabinowitz et al. Apr 2005 A1
20050089479 Rabinowitz et al. Apr 2005 A1
20050101936 Gonzales et al. May 2005 A1
20050122219 Petersen et al. Jun 2005 A1
20050129737 Johnson et al. Jun 2005 A1
20050131337 Phipps et al. Jun 2005 A1
20050142197 Moe et al. Jun 2005 A1
20050142198 Moe et al. Jun 2005 A1
20050150488 Dave et al. Jul 2005 A1
20050150489 Dunfield et al. Jul 2005 A1
20050163838 Moe et al. Jul 2005 A1
20050169989 Agarwal et al. Aug 2005 A1
20050171464 Phipps et al. Aug 2005 A1
20050176790 Bartholomaus Aug 2005 A1
20050177275 Harvey et al. Aug 2005 A1
20050192218 Ellis et al. Sep 2005 A1
20050258066 Conley et al. Nov 2005 A1
20060026035 Younkes et al. Feb 2006 A1
20060031099 Vitello et al. Feb 2006 A1
20060039959 Wessling et al. Feb 2006 A1
20060045865 Jacob et al. Mar 2006 A1
20060062812 Ross et al. Mar 2006 A1
20060067978 Heiler et al. Mar 2006 A1
20060069344 Southam et al. Mar 2006 A1
20060089858 Ling et al. Apr 2006 A1
20060134200 Vandoni et al. Jun 2006 A1
20060210632 Oury et al. Sep 2006 A1
20060216352 Nystrom et al. Sep 2006 A1
20060229570 Lovell et al. Oct 2006 A1
20060233718 Rabinowitz et al. Oct 2006 A1
20060251587 Rabinowitz et al. Nov 2006 A1
20060292219 Pather et al. Dec 2006 A1
20070020186 Stroppolo et al. Jan 2007 A1
20070031502 Pettersson et al. Feb 2007 A1
20070036853 Agarwal et al. Feb 2007 A1
20070071806 McCarty et al. Mar 2007 A1
20070074722 Giroux et al. Apr 2007 A1
20070104763 Jobdevairakkam et al. May 2007 A1
20070178052 Rabinowitz et al. Aug 2007 A1
20070184096 Ameri et al. Aug 2007 A1
20070185084 McKinney et al. Aug 2007 A1
20070186923 Poutiatine et al. Aug 2007 A1
20070190130 Mark et al. Aug 2007 A1
20070207207 Tzannis et al. Sep 2007 A1
20070260491 Palmer et al. Nov 2007 A1
20070286900 Herry Dec 2007 A1
20070299687 Palmer et al. Dec 2007 A1
20080147044 Palmer et al. Jun 2008 A1
20080164275 Poutiatine et al. Jul 2008 A1
20080166404 Tzannis et al. Jul 2008 A1
20080203107 Conley et al. Aug 2008 A1
20080268023 Palmer et al. Oct 2008 A1
20090010992 Palmer et al. Jan 2009 A1
20090048237 Palmer et al. Feb 2009 A1
20090131479 Palmer et al. May 2009 A1
20100105735 Palmer et al. Apr 2010 A1
20100137836 Palmer et al. Jun 2010 A1
20100253476 Poutiatine et al. Oct 2010 A1
20100256190 Palmer et al. Oct 2010 A1
20110091544 Palmer Apr 2011 A1
20110288128 Palmer et al. Nov 2011 A1
20120035216 Palmer et al. Feb 2012 A1
Foreign Referenced Citations (26)
Number Date Country
2776369 May 2006 CN
1 243 524 Sep 2002 EP
2114383 Jul 2010 EP
2309966 Aug 1997 GB
2003-525081 Aug 2003 JP
2004-511310 Apr 2004 JP
2004-531806 Oct 2004 JP
2005-199066 Jul 2005 JP
0016750 Mar 2000 WO
0057858 Oct 2000 WO
0130288 May 2001 WO
WO 0164182 Sep 2001 WO
0197780 Dec 2001 WO
WO 0232487 Apr 2002 WO
WO 02067903 Sep 2002 WO
WO 02067916 Sep 2002 WO
WO 02078594 Oct 2002 WO
2004069198 Aug 2004 WO
2004080515 Sep 2004 WO
2005032556 Apr 2005 WO
2006097361 Sep 2006 WO
2006103418 Oct 2006 WO
WO 2007 081949 Jul 2007 WO
WO 2008085764 Jul 2008 WO
WO 2008 085765 Jul 2008 WO
WO 2009021106 Feb 2009 WO
Non-Patent Literature Citations (213)
Entry
ACTIQ fact sheet printed Mar. 2004.
Berthold, et al., (2007) Oral Surg Oral med Oral Pathol Oral Radiol Endo, 84(2):119-24.
Bethune-Volters A, (2006) Anti-cancer drugs, vol. 17, No. 2, pp. 217-224.
Brendenberg, et al., 2003, Acta Universitatis Upsaliensis; Jan. 1983, Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 287.
Brendenberg, et al., 2003, European Journal of Pharmaceutical Sciences; 327-334.
Chauvin, Anesth Analg; 1989; 68(1): 1-4.
Coluzzi, et al., 1998, J Pain Symp Manage, 16(3):184-92.
Dale, et al., 2002, Acta Anaesth Scand, 46:759-770.
Darwish et al., 2007, J Clin Pharm 47: 56-63.
Darwish, et al., 2008, Clin Drug Invest, 28(1):1-7.
Darwish, et al., 2007, Expert Opin Pharmacother, 8(13):2011-6.
Darwish, et al., 2006, Clinical Pharmacokinetics, 45(8):843-50.
Darwish, et al., 2006, Clinical Therapies, 28(5):707-14.
Darwish, et al., 2006, Clinical Therapies, 28(5):715-24.
Darwish, et al., 2005, Clinical Pharmacokinetics, 44(12): 1279-86.
Demeules, et al., Eur J Anaesthesiol Suppl. 2003; 28:7-11.
Durfee, et al., 2006, American Journal Drug Delivery, 4(1):1-5(5).
Egan, et al., 2000, Anesthesiology, 92:665-73.
Farnsworth, et al., 1998, Anesth Analg, 86:138-40.
Fentora Package Insert, 100-800mcg dose of fentanyl; buccal absorption with approximately 50% absorbed transmucosally remainder swallowed/absorbed via GI tract. (p. 4 of package insert), 2006.
Gardner-Nix, et al., 2001, J Pain Symptom Manage, 22:627-630.
Geldner, et al., 1997, Paediatric Anaesthesia, 7:103-109.
Gerak, et al., 1998, Psychopharmacology, 137(2):164-74.
Good, et al., 2009, Palliative Medicine, 23:54-58.
Gordon, et al., 2006, Noncol Nurs Forum, 33(2):257-64.
Gram-Hansen, et al., 1988, Int J Clin Pharmacol Ther Toxicol, 26(6):323-4.
Mathieu, et al., 2006, Can J Anaesth, 53:60-66.
Haynes, et al., 1993, Can J Anaesth, 40(3):286-288.
Helmers, et al., 1989, Can J Anaesth, 36(5):494-497.
Henderson, et al., 1988, Anesthesiology, 68:671-675.
Jackson, et al., 2002, Journal of Pain and Sympt Management, 23(6):450-452.
Jackson, et al., 2006, Journal Clinical Psychopharmacology, 26(1):4-8.
James, et al., 2005, Clinical Radiology, 60:394-396.
Jeannet, et al., 1999, Eur J Paediatric Neurology, 3:73-77.
Joshi, et al., 1993, Indian Pediatr, 30(1):84-5.
Kaplan, et al., 1998, J Clin Pharmacol, 38(1): 14-21.
Karl, et al., 1997, Journal of Clinical Psychopharmacology, 17(3):169-172.
Karl, et al., 1992, Anesthesiology, 76:209-215.
Karl, et al., 1993, Anesthesiology, 78(5):885-91.
KGH Drug Information Bulletin, vol. 37(4) 2, 2004.
Khalil, et al., 1998, Paediatric Anaesthesia, (8):461-465.
Kogan, et al., 2002, Paediatric Anaesthesia, 12:685-689.
Kontinen, et al, 1993, Canadian Journal of Anesthesia, vol. 40, 829-834.
Kroboth, et al, 1995, J Clin Psychopharmacol, 15(4):259-62.
Kunz, et al., 1993, Journal of Pain and Sympt Management, 8(4):189-190.
Lennernas, et al., 2004, Br J Clin Pharmacol, 59(2):249-253.
Lichtor, et al., 1999, Anesth Anal, 89(3):732-8.
Lim, et al., 1997, Can J Anaesth, 44(7):723-6.
Lipworth, et al., 1989, Eur J Clin Pharmacol, 37:567-571.
McCann, et al., 2001, Anesthesia & Analgesia, 93:98-105.
Mendelson J, et al.; J Clin Pharmacol; 1997; 37:31-7.
Monk, et al., 1988, Drugs, 36:286-313.
Motwani JG, Lipworth BJ; Clin Pharmacokinet; 1991; 21(2):83-94.
Mystakidou K, et al.; Drug Deliv. 2006; 13(4):269-76.
Nath RP, et al.; J Clin Pharmacol; 1999; 39:619-23.
Naguib, et al., 2000, Anesth Analg, 91:473-9.
Odou, et al., 1999, Eur J Drug Metab Pharmacokinet, 24(1):1-7.
Odou, et al., 1998, Eur J Drug Metab Pharmacokinet, 23(2):87-91.
Okayama, et al., 1984, Eur J Clin Pharamcol, 26:151-155.
Pavlin, et al., Anesthesiology. Jan. 1996; 84(1):23-37.
Portenoy RK, et al.; Pain; 1999; 79:303-12.
Raza, et al., Can J Anaesth. Nov. 1989; 36(6):617-23.
Reisfield G, Wilson G; Journal of Palliative Medicine; 2007; 10(2):465-475.
Reynolds, et al., 2004, Pain, 110:182-188.
Roy et al, Pharm Res; 1990; 7:842-847.
Roy, SD and Flynn, GL; Pharm Research; 1989; 6(2): 147-151.
Scavone, et al., 1987, J Clin Psychpharmacol, 7(5):332-4.
Scavone, et al., 1992, Eur J Clin Pharmacol, 42(4):439-43.
Scavone, et al., 1986, J Clin Pharmacol, 26:208-10.
Scholz J, et al.; Clin Pharmacokin ; 1996; 31:275-292.
Schreiber, et al., 2006, The American Journal of Emergency Medicine, 24:397-401.
Schwagmeier, et al., 1998, Br J Clin Pharmacol, 46:203-69.
Sinatra, et al., 1996, Journal of Clinical Anesthesia, 8:123-129.
Stopperich, et al., 1993, Anesth Prog, 40(4):117-21.
Streisand JB, et al.; Anesthesiology; 1991; 75:223-9.
Streisand JB, et al.; Anesthesiology; 1998; 88:305-9.
Sufenta Package Insert, 2006.
Tweedy, et al., 2001, J Clin Psychopharmacol, 21(3):268-72.
Vercauteren, et al., 1988, Anaesthesia, 43:270-273.
Viitanen, et al., 1999, Can J Anesth, 46(8):766-771.
Walder, et al., Swiss Med Wkly. Jun. 12, 2004; 134(23-24):333-46.
Weinberg, et al., 1988, Clin Pharmacol Ther., 44(3):335-42.
Wheeler, et al., 2002, Paediatric Anesthesia, 12:594-599.
Willens, et al., 1993, Heart and Lung, 22:239-251.
Yager, et al., 1988, Am J Dis Child, 142:931-2.
Yeomans, et al., 2001, Vancouver Hospital and Health Science Center Drug and Therapeutics Newsletter, vol. 8(1) 2.
Zedie, et al., 1996, Clin Pharmacol Ther, 59:341-8.
Zhang, et al., 2002, Clinical Pharmacokinetics, 41(9):661-680.
Office Action for U.S. Appl. No. 11/429,904, mailed Sep. 17, 2008.
Office Action for U.S. Appl. No. 11/980,216, mailed Dec. 24, 2008.
Office Action for U.S. Appl. No. 11/650,230, mailed Sep. 25, 2008.
Office Action for U.S. Appl. No. 11/650,230, Mar. 10, 2009.
Office Action for U.S. Appl. No. 11/429,904, mailed Mar. 5, 2009.
Office Action for U.S. Appl. No. 11/650,227, mailed Dec. 9, 2008.
Office Action for U.S. Appl. No. 11/473,551, mailed Mar. 16, 2009.
Office Action for U.S. Appl. No. 11/473,551, mailed Sep. 26, 2008.
Office Action for U.S. Appl. No. 11/650,227, mailed Jul. 6, 2009.
Office Action for U.S. Appl. No. 11/980,216, mailed Jul. 20, 2009.
ISR WO2008/085764, Date mailed Jun. 23, 2008.
Abrams R, et al., Anesth Prog. 1993;40(3):63-6.
AHFS Drug Information, 28:08.08, 2157-2160, 2007.
Anlar S et al., Pharm Res, 11(2):231-6, 1994.
Bayrak F., et al., J Opiod Management, 3(2):74-78, 2007.
Bovill GJ, et al., Anesthesiology, 61:502-506, 1984.
Brusset A, et al. Clin Drug Invest, 18(5):377-89, 1999.
De Castro J, et al., Acta Anesth Belgica, 107-128, 1976.
de Vries M et al., Critical Reviews in Therapeutic Drug Carrier Systems, 8(3):271-303, 1991.
Ellmauer S, Anesth, 43(3):143-158, 1994.
Enting H. R, et al., J. Pain and Symptom Management, 29(2):213-217, 2005.
Guay J, Can J Anaesth, 39(1): 14-20, 1992.
Halliburton JR, Anesthesiology, 56(3): 229-233, 1988.
Hazardous Substances Data Bank (HSDB); (http://toxnet.nlm.nih.gov) Apr. 9, 2007; Name: Sufentanil; RN: 56030-54-7.
Helmers JH, et al., Eur J Anesth, 11(3):181-5, 1994.
Heshmati et al., Iran. J. Pharmacol. Therap., 5:131-133, 2006.
Ikinci G, et al., Int. J. Pharm, 277(1-2):173-8, 2004.
Kress, Clin. Therap., 31(6) 1177-1191, 2009.
Lehman K. A., et al., Acta Anaesthesiol Scand., 35:221-226, 1991.
Lehman K. A., et al., Acta Anaesthesiol Scand., 37:176-80, 1993.
Mather, Clin. Pharmacokinetics, 8: 422-446, 1983.
Molander L and Lunell E, Eur J Clin Pharmacol, 56(11):813-819, 2001.
Onsolis Package Insert Jul. 2009.
Portenoy RK, et al., Pain, 22(9):805-811, 2006.
Puig MM, et al., Int'l J Clin Pharmaco Ther and Toxicol, 27(5):229-34, 1989.
Rosow CE, Pharmacotherapy, 4:11-19, 1984.
Savoia G, et al., Minerva Anesth, 67(9 Suppl 1):206-16, 2001.
Siepmann et al., Int J Pharm., 25; 201(2):151-64, 2000.
Smith R.B, et al., J Clin Pharmacol., 26(2):120-4, 1986.
Van de Walle J, et al., Acta Anaesth Belg, 27(3):129-38, 2009.
Office Action for U.S. Appl. No. 11/650,174, mailed Oct. 13, 2010.
Office Action for U.S. Appl. No. 11/650,227, mailed Aug. 5, 2010.
Office Action for U.S. Appl. No. 11/825,251, mailed Aug. 5, 2010.
Office Action for U.S. Appl. No. 11/825,212, mailed Mar. 24, 2010.
Office Action for U.S. Appl. No. 11/825,212, mailed Aug. 31, 2010.
Office Action for U.S. Appl. No. 11/980,216, mailed Jan. 5, 2010.
Office Action for U.S. Appl. No. 11/980,216, mailed Jul. 2, 2010.
Office Action for U.S. Appl. No. 11/974,092, mailed Mar. 31, 2010.
Office Action for U.S. Appl. No. 12/187,937, mailed Sep. 16, 2010.
ISR WO2010/059504 mailed Mar. 17, 2010.
ISR WO2010/107761 mailed Jun. 21, 2010.
Office Action for U.S. Appl. No. 11/650,230, mailed Feb. 2, 2010.
Office Action for U.S. Appl. No. 11/650,230, mailed Jun. 16, 2010.
Good P, et al., Palliat Med., 23(1):54-58, 2009.
ISR PCT/US08/72445 WO 2009/021106, mailed Oct. 20, 2008.
ISR WO2007/133478, mailed Aug. 5, 2008.
ISR WO2008/002358, mailed Aug. 21, 2008.
ISR WO2007/081947, mailed Dec. 17, 2007.
ISR WO2007/081948, mailed Feb. 4, 2008.
ISR WO2007/081949, mailed Sep. 11, 2007.
ISR WO2008/085765, mailed Oct. 15, 2008.
Office Action for U.S. Appl. No. 11/825,251, mailed Sep. 21, 2009.
Office Action for U.S. Appl. No. 11/650,230, mailed Aug. 4, 2009.
Office Action for U.S. Appl. No. 11/974,092, mailed Sep. 30, 2009.
Office Action for U.S. Appl. No. 11/473,551, mailed Sep. 11, 2009.
Office Action for U.S. Appl. No. 11/429,904, mailed Aug. 20, 2009.
Restriction Requirement for U.S. Appl. No. 11/825,212, mailed Dec. 9, 2009.
Office Action for U.S. Appl. No. 11/825,251, mailed Dec. 15, 2009.
Office Action for U.S. Appl. No. 11/650,227, mailed Dec. 15, 2009.
“FDA Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics,” May 1999, pp. 1-E2.
“Triazolam” Drug Facts and Comparisons (Fiftieth Edition). 1996. Wolters Kluwer. p. 1619.
AcelRx Pharmaceuticals, Inc., “AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab™ Combination (ARX-03) in Treating Procedural Pain and Anxiety,” 2 pages, Press Release (Jan. 12, 2009).
Actiq package insert (Cephalon) (2004).
Ahmad, S. et al., “Fentanyl HCl iontophoretic transdermal system versus intravenous morphine pump after gynecologic surgery,” Arch. Gynecol. Obstet. 276:251-258 (2007).
Albert, J. M. et al., “Patient-Controlled Analgesia vs. Conventional Intramuscular Analgesia Following Colon Surgery,” Diseases of the Colon & Rectum, 31(2):83-86 (1988).
Brown et al., “Procedural Sedation in the Acute Care Setting,” Amer. Fam. Pharm. 71(1):85-90 (2005).
Chen et al., “Studies on Formulations of Fentanyl-Containing Oral Adhesive Tablets,” Chin. J. Pharm. 28(3):129-131 (1997).
Christie, J. M. et al., “Dose-titration, multi-center study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain,” J Clin Oncol., 16(10):3238-3245 (1998).
Coda, B.A. et al., “Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation,” Pain, 72:333-346 (1997).
Collins, L. M. C. et al., “The Surface Area of the Adult Human Mouth and Thickness of the Salivary Film Covering the Teeth and Oral Mucosa,” J. Dent. Res. 66(8):1300-1302 (1987).
Coluzzi, P. H. et al., “Breakthrough Cancer Pain: A Randomized Trial Comparing Oral Transmucosal Fentanyl Citrate (OTFC) and Morphine Sulfate Immediate Release (MSIR),” Pain, 91(1-2):123-130 (2001).
Darwish, M. et al., “Absolute and Relative Bioavailability of Fentanyl Buccal Tablet and Oral Transmucosal Fentanyl Citrate,” Journal of Clinical Pharmacology, 47:343-350 (2007).
Fisher, D.M. et al., “Pharmacokinetics of an Implanted Osmotic Pump Delivering Sufentanil for the Treatment of Chronic Pain,” Anesthesiology, 99(4):929-937 (Oct. 2003).
Friedman et al., “Population study of triazolam pharmacokinetics,” Br. J. Clin. Pharmacol., 22:639-642, 1986.
Goodwin et al., “Clinical Policy: Procedural Sedation and Analgesia in the Emergency Department,” Annals Emerg. Med. 45(2) 177-196, 2005.
Grass, J., “Patient-Controlled Analgesia,” Anesth. Analg., 101:S44-S61 (2005).
Halcion Package Insert, Apr. 2008.
Hicks et al., “The measurement of preoperative anxiety,” J. Royal Soc. Med., 81: 517-519, 1988.
Hicks, R. et al., “USP Medication Safety Forum: Medication Errors Involving Patient-Controlled Analgesia,” Joint Commission on Quality and Patient Safety, 34(12):734-742 (2008).
International Preliminary Report on Patentability for International Application No. PCT/US2007/000527, dated Feb. 24, 2009.
International Preliminary Report on Patentability for International Application No. PCT/US2007/000528, dated Jul. 8, 2008.
International Preliminary Report on Patentability for International Application No. PCT/US2007/000529, dated Jul. 8, 2008.
International Preliminary Report on Patentability for International Application No. PCT/US2007/089016, dated Jul. 7, 2009.
International Preliminary Report on Patentability for International Application No. PCT/US2007/089017, dated Jul. 7, 2009.
International Preliminary Report on Patentability for International Application No. PCT/US2007/089018, dated Jul. 7, 2009.
International Preliminary Report on Patentability for International Application No. PCT/US2010/052655, dated Apr. 17, 2012.
International Preliminary Report on Patentability for International Application No. PCT/US2009/064232, dated May 24, 2011.
International Preliminary Report on Patentability for International Application No. PCT/US2008/072445, dated Feb. 9, 2010.
International Search Report for International Application No. PCT/US2010/052655, mailed Apr. 4, 2011.
International Search Report for International Application No. PCT/US2007/089016, mailed Jun. 17, 2008.
International Search Report for International Application No. PCT/US2011/037401, mailed Aug. 19, 2011.
Jia et al., p. 10, in Novel controlled-release dosage forms for drugs, Chemical Industry Press (CIP), China (2005), Applicants' statement of relevance was considered.
Kraus et al., “Procedural sedation and analgesia in children,” Lancet 367:766-780 (2006).
Kress et al. “Sedation and Analgesia in the Intensive Care Unit”. Am J Respir Crit Care Med. 166; 2002:1024-1028.
Loeffler, “Oral Benzodiazepines and Conscious Sedation: A Review,” J. Oral Maxillofacial. Surg., 50(9) 989-997, 1992.
Paix, A. et al., “Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management,” Pain, 63:263-269 (1995).
Striebel, H. W. et al., “Patient-controlled intranasal analgesia (PCINA) for the management of postoperative pain: a pilot study,” J Clin Anesth, 8:4-8 (1996).
Striebel, H. W. et al., “Patient-controlled intranasal analgesia: a method for noninvasive postoperative pain management,” Anesth Analg, 83:548-551 (1996).
Supplementary European Search Report for European Application No. EP 08797363.2 dated Sep. 15, 2010.
Supplementary European Search Report for European Application No. EP 07716450.7 dated Apr. 6, 2011.
Van Vlymen et al., “Benzodiazepine Premedication,” Anesthesiology 90:740-747, 1999.
Viscusi, E. R. et al., “An iontophoretic fentanyl patient-activated analgesic delivery system for postoperative pain: a double-blind, placebo-controlled trial,” Anesth Analg., 102(1):188-194 (2006).
Viscusi, E. R. et al., “Patient-Controlled Transdermal Fentanyl Hydrochloride vs Intravenous Morphine Pump for Postoperative Pain: A randomized controlled trial,” JAMA, 291(11):1333-1341 (2004).
Written Opinion for International Application No. PCT/US2007/000529, mailed Sep. 11, 2007.
Written Opinion for International Application No. PCT/US2007/000528, mailed Feb. 4, 2008.
Written Opinion for International Application No. PCT/US2007/000527, mailed Dec. 17, 2007.
Written Opinion for International Application No. PCT/US2007/089018, mailed Oct. 15, 2008.
Written Opinion for International Application No. PCT/US2007/089016, mailed Jun. 17, 2008.
Written Opinion for International Application No. PCT/US2007/089017, mailed Jun. 23, 2008.
Written Opinion for International Application No. PCT/US2008/072445, mailed Oct. 20, 2008.
Written Opinion for International Application No. PCT/US2009/064232, mailed Mar. 17, 2010.
Written Opinion for International Application No. PCT/US2010/027437, mailed Jun. 21, 2010.
Written Opinion for International Application No. PCT/US2010/052655, mailed Apr. 4, 2011.
Written Opinion for International Application No. PCT/US2011/037401, mailed Aug. 19, 2011.
Singapore Search Report issued in Singapore Patent Application No. 201103689.4 on May 3, 2013.
Related Publications (1)
Number Date Country
20100130551 A1 May 2010 US